Cancer mortality data consistently favor people in the US versus their UK counterparts for a variety of reasons.

Quality of Life as an outcome in cancer clinical trials is an often overlooked but key aspect of the outcome of new cancer treatments.

Germline testing for inherited genetic variants is recommended to many people with cancer, yet such useful testing is notably underutilized.

Medical Science Liaisons are vital to foster relationships with HCPs, educating them about new treatments, and implementing clinical trials.

Most Americans use social media, making it a crucial tool in oncology, where new findings, biomarkers, treatments, and trials are presented.

Education about cancer clinical trials can increase trial enrollment by improving impressions, reducing fears, and raising awareness.

Patient Navigators increase the awareness and knowledge of people with cancer about clinical trials, leading to improved enrollment rates.

Choosing NGS first rather than Single-Gene Testing in cancer is a financially effective and diagnostically efficient strategy in many cases.

To enroll in clinical trials for targeted cancer therapies, people must be aware of them; thus, raising awareness is vital to enrollment.

Rural patients are underrepresented in cancer clinical trials, yet there are many steps to increase rural cancer trial participation rates.

After the COVID-19 pandemic, cancer clinical trials adopted a more patient-centric approach where trials work better for participants.

Cancer clinical trial diversity is poor, which matters because of different treatment responses. Solutions are vital to improve trials.

Half of all EU clinical trials are currently running behind schedule due to problems with new regulations for diagnostic medical devices.

A CMO is responsible for compound development success, so building awareness proactively and compliantly is critical for clinical trials.

Clinical trial failures are common and costly, yet they can teach us important lessons.

Clinical trials held in the UK have seen patient enrollment and trial numbers drop. Flexibility & creativity are needed to overcome issues.

Blood-based biomarkers (BBMs) hold promise for a fast, convenient, and simple means to accurately diagnose Alzheimer's Disease.

The European Medicines Agency (EMA) began mandatory use of the new Clinical Trials Information System (CTIS) as of Tuesday, Jan. 31, 2023.

Making decisions about medical treatment can be challenging and stressful. Furthermore, challenge and stress are magnified when deciding...

The development of life-saving treatments depends on clinical trials, which rely on ethical guidelines to ensure participants' safety.